Ilaris NIS in Korea

NCT06838143 · tracked via the Priya Life Science South Korea tracker

Sponsor

Novartis Pharmaceuticals

Phase

Observational

Started

2025-03-29

Last updated

2026-05-19

Condition(s) studied

Hereditary Periodic Fever SyndromesCryopyrin-associated Periodic Syndromes (CAPS)Colchicine Resistance Familial Mediterranean Fever (crFMF)TNF Receptor Associated Periodic Syndrome (TRAPS)Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)Systemic Juvenile Idiopathic Arthritis (sJIA)

Investigational drug(s) / intervention(s)

Ilaris

Ilaris: Prospective observational study. There is no treatment allocation.

Study summary

This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).

Eligibility

Sex

ALL

Min age

2 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: 1. Written informed consent/assent of the patient or their legal representative/parent (≥2 year and \<19 year-old pediatric patient) for voluntarily participating in this study 2. Age: ≥2 year and \<19 year-old pediatric and ≥19 year-old adult hereditary periodic fever syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) patients and ≥2 year and \<19 year-old sJIA patients 3. Patient who have an agreement to be treated or who have already started treatment with Ilaris in accordance with the approved label information Exclusion Criteria: 1. Patients receiving Ilaris treatment for autoimmune disease other than CAPS, crFMF, TRAPS, HIDS/MKD or sJIA 2. Patients participating in an interventional clinical trial which would have an impact on routine clinical treatment

Primary outcome measure(s)

Incidence of adverse events and serious adverse events — Up to 104 weeks from Ilaris treatment
Adverse events and serious adverse events in hereditary periodic fever syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) and sJIA patients treated with Ilaris.

Trial sites (1)

Facility	City	Region	Status
Novartis Investigative Site	Seoul	South Korea	Recruiting

More Novartis Pharmaceuticals trials in South Korea

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer Active, not recruiting

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN Recruiting

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis Active, not recruiting

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Active, not recruiting

Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06838143 on ClinicalTrials.gov ↗ ← All trials in South Korea